Metriana
Perspectives
Clinical and structural analysis of weight health from the team building Metriana.
19 min read
The GLP-1 Discontinuation Crisis: Why Half of Patients Stop in Year One
Between 46% and 65% of patients on GLP-1 medications for weight loss discontinue within their first year. The leading causes are not failures of the medication. They are failures of the support structure around it — and most are directly preventable with structured clinical care.
Read article
17 min read
Weight Regain After GLP-1s: What the Research Shows and What to Do About It
Most patients who stop GLP-1 medications regain the majority of lost weight within 12 to 18 months. Cardiovascular risk rebounds, metabolic gains reverse, and the restart cycle compounds claims year over year. The research is clear on what breaks the cycle — but it requires a different kind of GLP-1 program than most employees have access to.
Read article
15 min read
Why Medication Alone Won't Produce Durable Weight Health
GLP-1 medications suppress appetite. They do not build the behavioral habits, protect the muscle mass, or address the psychological drivers of weight that determine what happens when the prescription changes. Behavioral support combined with GLP-1 therapy outperforms medication alone by a measurable margin.
Read article
12 min read
The Hidden Cost of Unmanaged GLP-1 Use
GLP-1 medications cost $1,000 to $1,500 per patient per month, but the pharmacy line is only part of the bill. Side-effect claims, adherence failure, the regain cycle, and compounding risks generate four hidden cost categories that decide whether the spend pays back.
Read article
6 min read
Why Employer Weight Management Benefits Fail — And What the Research Shows
Most employer-sponsored weight management programs achieve fewer than five percent long-term success. The cause is delivery design, not curriculum quality.
Read article